Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 571 participants.
Also called NCT02526524
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 571 participants
- Sponsor
- Elcelyx Therapeutics, Inc.
- Registry
-
NCT02526524
-
- Other papers using this trial's data
- Improved glycemic control with minimal systemic metformin exposure: Effects of Metformin Delayed-Release (Metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Puerto Rico
- Registry status
- Completed
Technical summary
Registry record NCT02526524. Randomized; quadruple masking; primary purpose treatment. Start 2015-09 (registry gives no type); primary completion 2016-09 (actual). Results posted on 2018-04-27.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Met DR
- Intervention (Drug)
- Met IR
- Intervention (Drug)
- Placebo
- Lead sponsor
- Elcelyx Therapeutics, Inc.
Record details
- Record id
cardio:ct-nct02526524- Content hash
adf5b80b231db322fa72a17bf5756dafac9b8ce1ee2444eb3c4c6b8fa42e73c1